Loading…

Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker

BACKGROUND: CD26 is an ectoenzyme with dipeptidyl peptidase 4 (DPP4) activity expressed on a variety of cell types. Considering that serum CD26 levels have been previously associated with different cancers, we examined the potential diagnostic value of serum CD26 levels in gastric cancer. METHODS: S...

Full description

Bibliographic Details
Main Authors: Boccardi, Virginia, Marano, Luigi, Rossetti, Rosaria Rita Amalia, Rizzo, Maria Rosaria, di Martino, Natale, Paolisso, Giuseppe
Format: Online Article Text
Language:English
Published: BioMed Central 2015
Subjects:
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608357/
https://www.ncbi.nlm.nih.gov/pubmed/26471376
http://dx.doi.org/10.1186/s12885-015-1757-0
_version_ 1782395660688949248
author Boccardi, Virginia
Marano, Luigi
Rossetti, Rosaria Rita Amalia
Rizzo, Maria Rosaria
di Martino, Natale
Paolisso, Giuseppe
author_facet Boccardi, Virginia
Marano, Luigi
Rossetti, Rosaria Rita Amalia
Rizzo, Maria Rosaria
di Martino, Natale
Paolisso, Giuseppe
author_sort Boccardi, Virginia
collection PubMed
description BACKGROUND: CD26 is an ectoenzyme with dipeptidyl peptidase 4 (DPP4) activity expressed on a variety of cell types. Considering that serum CD26 levels have been previously associated with different cancers, we examined the potential diagnostic value of serum CD26 levels in gastric cancer. METHODS: Soluble serum CD26 levels were measured in pre and postoperative serum samples of 30 patients with gastric cancer and in 24 healthy donors by a specific ELISA kit. RESULTS: We found significantly lower serum CD26 levels in patients with gastric cancer (557.7 ± 118.3 pg/mL) compared with healthy donors (703.4 ± 170.3 pg/mL). Moreover patients with HER2 positive tumors had significantly lower CD26 serum levels (511.8 ± 84.8 pg/mL) compared with HER2 negative tumors (619.1 ± 109.9 pg/mL, p = 0.006). A binary logistic model having gastric cancer as the dependent variable while age, gender, CEA, CA19.9 and CD26 levels as covariates, showed that CD26 serum levels were independently associated with gastric cancer presence. Indeed after 3 months from surgery serum CD26 levels significantly increased (700.1 ± 119.9 pg/mL vs 557.7 ± 118.3 pg/ml) in all patients (t = −4.454, p < 0.0001). CONCLUSIONS: This is a preliminary study showing that the measurement of serum CD26 levels could represent an early detection marker for gastric cancer.
format Online
Article
Text
id pubmed-4608357
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46083572015-10-17 Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker Boccardi, Virginia Marano, Luigi Rossetti, Rosaria Rita Amalia Rizzo, Maria Rosaria di Martino, Natale Paolisso, Giuseppe BMC Cancer Research Article BACKGROUND: CD26 is an ectoenzyme with dipeptidyl peptidase 4 (DPP4) activity expressed on a variety of cell types. Considering that serum CD26 levels have been previously associated with different cancers, we examined the potential diagnostic value of serum CD26 levels in gastric cancer. METHODS: Soluble serum CD26 levels were measured in pre and postoperative serum samples of 30 patients with gastric cancer and in 24 healthy donors by a specific ELISA kit. RESULTS: We found significantly lower serum CD26 levels in patients with gastric cancer (557.7 ± 118.3 pg/mL) compared with healthy donors (703.4 ± 170.3 pg/mL). Moreover patients with HER2 positive tumors had significantly lower CD26 serum levels (511.8 ± 84.8 pg/mL) compared with HER2 negative tumors (619.1 ± 109.9 pg/mL, p = 0.006). A binary logistic model having gastric cancer as the dependent variable while age, gender, CEA, CA19.9 and CD26 levels as covariates, showed that CD26 serum levels were independently associated with gastric cancer presence. Indeed after 3 months from surgery serum CD26 levels significantly increased (700.1 ± 119.9 pg/mL vs 557.7 ± 118.3 pg/ml) in all patients (t = −4.454, p < 0.0001). CONCLUSIONS: This is a preliminary study showing that the measurement of serum CD26 levels could represent an early detection marker for gastric cancer. BioMed Central 2015-10-15 /pmc/articles/PMC4608357/ /pubmed/26471376 http://dx.doi.org/10.1186/s12885-015-1757-0 Text en © Boccardi et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Boccardi, Virginia
Marano, Luigi
Rossetti, Rosaria Rita Amalia
Rizzo, Maria Rosaria
di Martino, Natale
Paolisso, Giuseppe
Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker
title Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker
title_full Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker
title_fullStr Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker
title_full_unstemmed Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker
title_short Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker
title_sort serum cd26 levels in patients with gastric cancer: a novel potential diagnostic marker
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608357/
https://www.ncbi.nlm.nih.gov/pubmed/26471376
http://dx.doi.org/10.1186/s12885-015-1757-0
work_keys_str_mv AT boccardivirginia serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker
AT maranoluigi serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker
AT rossettirosariaritaamalia serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker
AT rizzomariarosaria serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker
AT dimartinonatale serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker
AT paolissogiuseppe serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker